Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Mitoxantrone].

I Pericot1, X Montalban

  • 1Unidad de Neuroinmunología Clínica, Escuela de Enfermería, Hospital Universitario Vall d'Hebron Barcelona, Spain. imma@comg.es

Neurologia (Barcelona, Spain)
|July 3, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthetic MRI in Progressive MS: Associations with Disability.

AJNR. American journal of neuroradiology·2025
Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)].

Revista de neurologia·2024
Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I)].

Revista de neurologia·2024
Same author

[15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part II)].

Revista de neurologia·2023
Same author

[15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part I)].

Revista de neurologia·2023
Same author

Validation of a New Semiautomated Segmentation Pipeline Based on the Spinal Cord Toolbox DeepSeg Algorithm to Estimate the Cervical Canal Area.

AJNR. American journal of neuroradiology·2023
Same journal

[Amyotrophic neuralgia secondary to Vaxzevria (AstraZeneca) COVID-19 vaccine].

Neurologia (Barcelona, Spain)·2024
Same journal

[SARS-CoV-2 infection: Possible underdiagnosis of cerebral venous sinus thrombosis].

Neurologia (Barcelona, Spain)·2024
Same journal

[Bell's palsy following COVID-19 vaccination: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Parsonage-Turner syndrome post-infection by SARS-CoV-2: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Acute transverse myelitis following SARS-CoV-2 infection].

Neurologia (Barcelona, Spain)·2024
Same journal

[Neurological complications in critical patients with COVID-19].

Neurologia (Barcelona, Spain)·2024
See all related articles

Mitoxantrone effectively reduces relapse rates and delays disability progression in multiple sclerosis (MS) patients. However, its use is limited by potential cardiotoxicity, with a maximum recommended cumulative dose.

Area of Science:

  • Immunology
  • Neurology
  • Oncology

Context:

  • Mitoxantrone is an antineoplastic agent with significant immunosuppressive properties.
  • Multiple Sclerosis (MS) encompasses relapsing remitting (RRMS), secondary progressive (SPMS), and progressing relapsing (PRMS) forms.

Purpose:

  • To evaluate the efficacy and safety of mitoxantrone in managing multiple sclerosis.
  • To determine the impact of mitoxantrone on disease relapse rates and disability progression.

Summary:

  • Mitoxantrone demonstrates a statistically significant reduction in relapse rates and delays disability progression in patients with RRMS and SPMS.
  • The drug is generally well-tolerated, but cardiotoxicity risk increases with cumulative dosage.
  • The maximum recommended cumulative dose is 140 mg/m2.

Related Experiment Videos

Impact:

  • Mitoxantrone offers a therapeutic option for active MS, approved by the FDA in 2000 for specific MS subtypes.
  • Treatment duration may be limited by cumulative dose-related cardiotoxicity.
  • This highlights the need for careful patient monitoring and dose management in MS treatment.